Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Business Wire
New publication shows that Prospera-guided care helped 75% of low-risk patients safely avoid routine transbronchial biopsies performed at 9 months AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new prospective clinical trial in Transplantation Direct. The study, which was conducted by The Ohio State University Wexner Medical Center (OSU-WMC), was initiated to explore whether donor-derived cell-free DNA (dd-cfDNA) surveillance, and specifically Prospera-guided monitoring, could reduce the number of invasive biopsies for patients following lung transplantation.Lung transplant patients are typically monitored with transbronchial biopsies – at one, three, six, nine, and 12 months after transplantation. These procedures are invasive, costly and associated with significant morbidity¹.As transplant volumes increased at OSU-WMC, the center launched a quality assurance and performance
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy OutcomesBusiness Wire
- Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards [Seeking Alpha]Seeking Alpha
- Natera Submits Signatera™ CDx PMA to FDABusiness Wire
- A Look At The Fair Value Of Natera, Inc. (NASDAQ:NTRA) [Yahoo! Finance]Yahoo! Finance
- Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart TransplantationBusiness Wire
NTRA
Earnings
- 11/6/25 - Miss
NTRA
Sec Filings
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- NTRA's page on the SEC website